Extracorporeal removal of circulating immune complexes: From non-selective to patient-specific

Blood Purification

Volumn 18, Issue 2, 2000, Pages 156-160

  Matic, Goran ^a,c   Schütt, Wolfgang ^b   Winkler, Roland E ^a   Tiess, Michael ^a   Ramlow, Wolfgang ^a  

^a Dialyse Gemeinschaft Nord eV   (Germany)

^b JMS Co Ltd   (Japan)

^c DGN eV   (Germany)

Author keywords

Cryofiltration; Glomerulonephritis; Immunoadsorption; Membrane differential filtration; Plasma exchange; Plasmapheresis; Protein A; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C1Q; PLASMA PROTEIN; PROTEIN A;

CANCER; COMPLEMENT ACTIVATION; EXTRACORPOREAL CIRCULATION; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOADSORPTION; INFECTION; INFLAMMATION; KIDNEY; MEMBRANE FILTER; PLASMAPHERESIS; PRIORITY JOURNAL; SERUM SICKNESS; SHORT SURVEY; VASCULITIS;

EID: 0342656569     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014441     Document Type: Short Survey

References (23)

1. Davies KA: Michael Mason Prize Essay 1995. Complement, immune complexes and systemic lupus erythematosus. Br J Rheumatol 1996;35:5-23.
2. Danning CL, Illei GG, Boumpas DT: Vasculitis associated with primary rheumatologic diseases. Curr Opin Rheumatol 1998;10:58-65.
3. Reynolds WJ, Yoon SJ, Emin M, Chapman KR, Klein MH: Circulating immune complexes in rheumatoid arthritis: A prospective study using five immunoassays. J Rheumatol 1986;13:700-706.
4. Lockwood CM, Pinching AJ, Sweny P, Rees AJ, Pussell B, Uff J, et al: Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1977;i:63-67.
5. Gauthier VJ, Abrass CK: Circulating immune complexes in renal injury. Semin Nephrol 1992;12:379-394.
6. Smith JW: Therapeutic apheresis in the United States: Current indications and directions (editorial). Ther Apher 1999;3:1-3.
7. Rossen RD, Hersh EM, Sharp JT, McCredie KB, Gyorkey F, Suki WN, et al: Effect of plasma exchange on circulating immune complexes and antibody formation in patients treated with cyclophosphamide and prednisone. Am J Med 1977;63:674-682.
8. Jones JV, Cumming RH, Bueknall RC, Asplin CM: Plasmaphercsis in the management of acute systemic lupus erythematosus? Lancet 1976:i:709-711.
9. Phillips TM, Holohan TV, Korac S, More NS, Queen WD: The pathophysiology of circulating immune complexes: Their role in host-tumor interactions and removal by immunoadsorption therapy. ContempTop Immunobiol 1985; 15:111-137.
10. Wallace DJ, Barnett EV, Nichols S, Hancock W, Vibert G, Curd J. et al: Immunologic dynamics in cryapheresis for rheumatoid arthritis. J Rheumatol 1983;10:894-900.
11. Sueoka A: Present status of apheresis technologies: Part 2. Membrane plasma fractionator (editorial). Ther Apher 1997;1:135-146.
12. Siami GA, Siami FS: Cryofiltration apheresis in the United States. Ther Apher 1998;2:228-235.
13. Sueoka A: Present status of apheresis technologies: Part 3. Adsorbent. Ther Apher 1997;1: 271-283.
14. Schneider M, Berning T, Waldendorf M, Glaser J, Gerlach U: Immunoadsorbent plasma perfusion in patients with systemic lupus erythemalosus. J Rheumatol 1990;17:900-907.
15. Matic G, Hofmann D, Winkler R, Tiess M, Michelsen A, Schneidewind JM, et al: Removal of immunoglobulins by a protein A versus an anti-human-immunoglobulin-G-based system: Evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000; in press.
16. Howe RB, Christie DJ: Protein A immunoadsorption treatment in hematology: An overview. J Clin Apheresis 1994;9:31-32.
17. Snyder HW Fr, Cochran SK, Balint JP Jr, Bertram JH, Mittelman A, Guthrie TH Jr. et al: Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992;79:2237-2245.
18. Fennelly DW, Norton L, Sznol M, Hakes TB: A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer. Cancer 1995;75:2099-2102.
19. Braun N, Risler T: Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999;3:240-245.
20. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Buhler R, et al: Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996;348:1208-1211.
21. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM: Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999;5:32-39.
22. Hiepe F, Pfuller B, Wolbart K, Bruns A, Leinenbach HP, Hepper M, et al: C1q: A multifunctional ligand for a new immunoadsorption treatment. Ther Apher 1999;3:246-251.
23. Eil A, Matic G, Drobnik W, Ullrich H, Glück T, Pickenpack A, et al: Safety and kinetics of the C1q-adsorber (abstract). 2nd Int Congr Int Soc for Apheresis, Saarbrücken, 1999.